Intelligence, in the open.

Spectrum Exits the Poziotinib Exon 20 Program: Four Trials Halted, Stated Reasons Explicitly Exclude Safety

Four terminated or suspended studies, zero Phase 3 enrollees, active FDA redesign talks: stated reasons across all Spectrum-sponsored poziotinib terminations explicitly exclude safety — the regulatory and strategic picture is the story.